Trial reportFrontiers in veterinary science2026
Pilot study demonstrating safety and efficacy of intravenous allogeneic uterine-derived mesenchymal stromal cell therapy in cats with naturally occurring osteoarthritis.
Trial report in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The objective of this study was to evaluate the tolerability and efficacy at 3 months of intravenous (IV) allogeneic uterine-derived mesenchymal stromal cells (UMSCs) for osteoarthritis (OA) in client-owned cats. Methods: This was a randomized, masked, placebo-controlled pilot study conducted across six veterinary clinics. Thirty-five client-owned cats with naturally occurring OA were randomly assigned to receive two intravenous injections, given 14 days apart, of one of three treatments: 5 million (5M) UMSCs, 20 million (20M) UMSCs, or saline placebo. Client-Specific Outcome Measures (CSOM), Owner Overall Assessment (OOA), Veterinarian Overall Assessment (VOA) and Veterinarian Pain Assessment (VPA) were recorded at day 0, 14, 30, 60 and 90. Results: At day 90, predefined treatment success was achieved in: CSOM and OOA for 7/9(78%) 5M UMSC and 10/12(83%) 20M UMSC treated cats compared to 4/11(36.4%) placebo-treated cats for both outcomes; VOA for 4/8(50%) 5M UMSC and 8/12(67%) 20M UMSC treated cats compared to 2/10(20%) placebo-treated cats; and VPA for 6/8(75%) 5M UMSC and 10/12(83%) 20M UMSC treated cats compared to 5/11(45%) placebo-treated cats. Treatment-related adverse events were observed in 1/10 (10%) 5M UMSC treated cats, 5/13 (38%) 20M UMSC treated cats, and 2/12 (16.7%) saline treated cats. The most common treatment related events reported in the first 24 hours were transient vomiting or nausea, weakness, lethargy, hypersalivation, tachypnea and malodorous breath. Discussion: This study demonstrated that IV administration of allogeneic UMSCs was well tolerated and showed improvement in owner and veterinarian outcomes at both 5M UMSC and 20M UMSC dosing to at least 3 months in cats with naturally occurring OA. Intravenous MSC therapy shows promise for cats with OA and warrants further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.